AstraZeneca (AZN) announced this week that it has acquired joint development and commercialization rights to a cancer candidate from Daiichi Sankyo. As part of the deal, AZN will be paying as much as $6.9 billion to Daiichi Sankyo of Japan. The two companies will be developing and commercializing Daiichi Sankyo’s proprietary antibody-drug conjugate (ADC) trastuzumab … Continue reading “AstraZeneca Acquires Joint Development and Commercialization Rights to a Very Exciting Cancer Candidate”
Tag: AZN
Biotech & Pharma
AstraZeneca’s Experimental Lupus Treatment Fails to Hit Primary Endpoint
Anifrolumab, AstraZeneca Plc's experimental treatment for lupus, has missed its primary endpoint in a study.…
September 3, 2018
Biotech & Pharma
AstraZeneca (AZN) Battles Crestor Competition
AstraZeneca recently received FDA approval to use Crestor, its blockbuster cholestrol drug, to treat children…
June 29, 2016